Parkinson's disease gene therapy - Avigen

Drug Profile

Parkinson's disease gene therapy - Avigen

Latest Information Update: 27 Jun 2003

Price : $50

At a glance

  • Originator Avigen
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 27 Jun 2003 Discontinued - Preclinical for Parkinson's disease in USA (Injection)
  • 16 Aug 2002 This gene therapy is still in active development
  • 28 Jul 1998 An animal study was added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top